Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M L Berman

Showing results (151-160 of 171) with videos related to

Pageof 18
Sort By:
International Journal of Cancer|May 8, 1993
Oral contraceptives and endometrial cancer: do other risk factors modify the association?J L Stanford, L A Brinton, M L Berman, et al.
Gynecologic Oncology|November 1, 1986
Accurate laboratory predictions of the clinical response of patients with advanced ovarian cancer to treatment with cyclophosphamide, doxorubicin, and cisplatinJ A Stratton, P R Kucera, M A Rettenmaier, et al.
Gynecologic Oncology|July 1, 1994
Extent of disease as an indication for pelvic radiation following radical hysterectomy and bilateral pelvic lymph node dissection in the treatment of stage IB and IIA cervical carcinomaB J Monk, D S Cha, J L Walker, et al.
International Journal of Epidemiology|June 1, 1997
Intrauterine device use and endometrial cancer riskS R Sturgeon, L A Brinton, M L Berman, et al.
Gynecologic Oncology|September 10, 1999
Interstitial brachytherapy for vaginal recurrences of endometrial carcinomaK Tewari, F Cappuccini, W R Brewster, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 1, 1995
Assessment of dose-intensive therapy in suboptimally debulked ovarian cancer: a Gynecologic Oncology Group studyW P McGuire, W J Hoskins, M F Brady, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|July 1, 1993
Relation of endometrial cancer risk to past and contemporary body size and body fat distributionC A Swanson, N Potischman, G D Wilbanks, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|October 1, 1994
Endometrial cancer risk in relation to serum lipids and lipoprotein levelsC A Swanson, N Potischman, R J Barrett, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|April 1, 1998
Analysis of histopathological features of endometrioid uterine carcinomas and epidemiologic risk factorsS R Sturgeon, M E Sherman, R J Kurman, et al.
Gynecologic Oncology|May 1, 1992
Immunotherapy of ovarian cancer. II. In vitro generation and characterization of lymphokine-activated killer T cells from the peripheral blood of recurrent ovarian cancer patientsJ A Lucci, A Manetta, F Cappuccini, et al.
Pageof 18

Showing results (151-160 of 171) with videos related to

Sort By:
Pageof 18
International Journal of Cancer|May 8, 1993
Oral contraceptives and endometrial cancer: do other risk factors modify the association?J L Stanford, L A Brinton, M L Berman, et al.
Gynecologic Oncology|November 1, 1986
Accurate laboratory predictions of the clinical response of patients with advanced ovarian cancer to treatment with cyclophosphamide, doxorubicin, and cisplatinJ A Stratton, P R Kucera, M A Rettenmaier, et al.
Gynecologic Oncology|July 1, 1994
Extent of disease as an indication for pelvic radiation following radical hysterectomy and bilateral pelvic lymph node dissection in the treatment of stage IB and IIA cervical carcinomaB J Monk, D S Cha, J L Walker, et al.
International Journal of Epidemiology|June 1, 1997
Intrauterine device use and endometrial cancer riskS R Sturgeon, L A Brinton, M L Berman, et al.
Gynecologic Oncology|September 10, 1999
Interstitial brachytherapy for vaginal recurrences of endometrial carcinomaK Tewari, F Cappuccini, W R Brewster, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 1, 1995
Assessment of dose-intensive therapy in suboptimally debulked ovarian cancer: a Gynecologic Oncology Group studyW P McGuire, W J Hoskins, M F Brady, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|July 1, 1993
Relation of endometrial cancer risk to past and contemporary body size and body fat distributionC A Swanson, N Potischman, G D Wilbanks, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|October 1, 1994
Endometrial cancer risk in relation to serum lipids and lipoprotein levelsC A Swanson, N Potischman, R J Barrett, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|April 1, 1998
Analysis of histopathological features of endometrioid uterine carcinomas and epidemiologic risk factorsS R Sturgeon, M E Sherman, R J Kurman, et al.
Gynecologic Oncology|May 1, 1992
Immunotherapy of ovarian cancer. II. In vitro generation and characterization of lymphokine-activated killer T cells from the peripheral blood of recurrent ovarian cancer patientsJ A Lucci, A Manetta, F Cappuccini, et al.
Pageof 18